Rheumatoid Arthritis - Pipeline Review, H2 2013


Naperville, IL -- (SBWIRE) -- 09/09/2013 -- Reportstack, provider of premium market research reports announces the addition of Rheumatoid Arthritis - Pipeline Review, H2 2013 market report to its offering
Rheumatoid Arthritis - Pipeline Review, H2 2013


, 'Rheumatoid Arthritis - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Rheumatoid Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis. Rheumatoid Arthritis - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- A snapshot of the global therapeutic scenario for Rheumatoid Arthritis.
- A review of the Rheumatoid Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Rheumatoid Arthritis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Rheumatoid Arthritis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Rheumatoid Arthritis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned

Alcon, Inc.
Bristol-Myers Squibb Company
Johnson & Johnson
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Biogen Idec Inc.
Amgen Inc.
Antares Pharma, Inc.
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Inovio Biomedical Corporation
MedImmune LLC
Isis Pharmaceuticals, Inc.
Biotest AG
Merck & Co., Inc.
Santen Pharmaceutical Co., Ltd.
Emergent BioSolutions Inc.
Novo Nordisk A/S
Infinity Pharmaceuticals, Inc.
Albany Molecular Research, Inc.
Plexxikon Inc.
arGentis Pharmaceuticals, LLC
Reliance Life Sciences Pvt. Ltd.
MediGene AG
Celltrion, Inc.
Nycomed International Management GmbH
TiGenix NV
Pacira Pharmaceuticals, Inc.
Samyang Corporation
Astellas Pharma Inc.
Biocon Limited
Cephalon, Inc.
Chugai Pharmaceutical Co. Ltd
Cipla Ltd.
Daewoong Pharmaceutical Co., Ltd.
Gedeon Richter Plc.
Glenmark Pharmaceuticals Ltd.
Kissei Pharmaceutical Co., Ltd.
Mitsubishi Tanabe Pharma Corporation
Pfizer Inc.
Santarus, Inc.
Toyama Chemical Co. Ltd
UCB Group
Vertex Pharmaceuticals Incorporated
Zydus Cadila Healthcare Limited
Cell Therapeutics, Inc.
Genmab A/S
Hadasit Medical Research Services & Development Ltd
Sandoz Inc.
Paratek Pharmaceuticals, Inc.
CEL-SCI Corporation
Celgene Corporation
Onyx Pharmaceuticals, Inc.
Incyte Corporation
XTL Biopharmaceuticals Ltd.
Merck KGaA
Bone Medical Limited
Access Pharmaceuticals, Inc.
3SBio Inc.
Addex Pharmaceuticals
EntreMed, Inc.
Hollis-Eden Pharmaceuticals, Inc.
Can-Fite BioPharma Ltd.
Idera Pharmaceuticals, Inc.
Karo Bio
Ligand Pharmaceuticals Incorporated
Almirall, S.A.
Lupin Limited
Medivir AB
Mesoblast Ltd
PROLOR Biotech, Inc.
Nutra Pharma Corporation
Compugen Ltd.
Lexicon Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc.
Portola Pharmaceuticals, Inc.
Chelsea Therapeutics, Inc.
Yuhan Corporation
Zenotech Laboratories Limited
Regeneron Pharmaceuticals, Inc.
Pharmacyclics, Inc.
Protalix BioTherapeutics, Inc.
Tolerx, Inc.
MorphoSys AG
Dongwha Pharm Co., Ltd.
Boryung Pharmaceutical Co., Ltd.
Green Cross Corporation
Hanall Pharmaceutical Co., Ltd.
Cytos Biotechnology AG
LG Life Sciences, Ltd
AnGes MG, Inc.
Biotie Therapies Corp.
Transition Therapeutics Inc.
Galapagos NV
Synta Pharmaceuticals Corp.
Panacea Biotec Limited
CrystalGenomics, Inc.
Sareum Holdings plc
Protalex, Inc.
Proximagen Neuroscience plc.
Newron Pharmaceuticals S.p.A.
DiaMedica Inc.
Morphotek, Inc.
Spectrum Pharmaceuticals, Inc.
Advinus Therapeutics Pvt. Ltd.
Auspex Pharmaceuticals
Affimed Therapeutics AG
Chipscreen Biosciences Ltd
AcurePharma AB
Ambit Biosciences Corporation
Viron Therapeutics, Inc.
Immupharma Plc
Palau Pharma S.A
Philogen S.p.A.
Probiodrug AG
Farmacija d.o.o. Tuzla
Pharmagenesis, Inc.
Acceleron Pharma, Inc.
Phenex Pharmaceuticals AG
Neovacs SA
MIKA Pharma GmbH
Hutchison MediPharma Limited
CREABILIS Therapeutics S.r.l.
Artielle ImmunoTherapeutics, Inc.
BioNumerik Pharmaceuticals, Inc.
InCode BioPharmaceutics, Inc.
Aegera Therapeutics Inc.
Amura Holdings Ltd.
JADO Technologies GmbH.
Alder Biopharmaceuticals Inc.
Circassia Holdings Ltd.
Coronado Biosciences, Inc.
MacroGenics, Inc.
Catabasis Pharmaceuticals, Inc.
Antyra, Inc.
Recoly N.V.
Regado Biosciences.
Opsona Therapeutics Ltd.
Asahi Kasei Pharma
Five Prime Therapeutics, Inc.
Vaccinex, Inc.
Syntrix Biosystems, Inc.
Alloksys Life Sciences BV
MSM Protein Technologies, Inc.
Vascular Biogenics Ltd.
Indus Biotech Private Limited
Xention Limited
Txcell SA
Endocyte, Inc.
Theraclone Sciences, Inc.
TcL Pharma SAS
Versartis, Inc.
Cardax Pharmaceuticals, Inc.
Inimex Pharmaceuticals, Inc.
Logical Therapeutics, Inc.
Omeros Corporation
Xencor, Inc.
Cornerstone Therapeutics Inc.
Acetylon Pharmaceuticals, Inc.
Trillium Therapeutics Inc.
BaroFold, Inc.
Cellceutix Corporation
VentiRx Pharmaceuticals, Inc.
Provid Pharmaceuticals, Inc.
Resolvyx Pharmaceuticals, Inc
Biokine Therapeutics Ltd.
OncoImmune, Inc.
Medistem, Inc.
Avesthagen Limited
KAHR medical Ltd.
SuppreMol GmbH
Viromed Co., Ltd.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Aphoenix, Inc.
Covagen AG
Domainex Ltd.
Dynamix Pharmaceuticals Ltd.
Amplimmune, Inc.
Lycera Corp.
Perseid Therapeutics LLC
Sinil Pharma Ltd.
OHR Pharmaceutical Inc.
ImmunoFrontier, Inc.
Femta Pharmaceuticals, Inc.
ModiQuest B.V.
Mycenax Biotech Inc.
Bio Sidus S.A.
Cellmid Ltd
Mebiopharm Co., Ltd.
ToleroTech Inc.
CellAct Pharma GmbH
Diurnal Ltd

To view the table of contents for this market research report please visit